Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr, KATHERINE Investigators

Open source

DOI: 10.1056/nejmoa1814017
Published: 2019 Feb 14
Container: The New England journal of medicine
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa1814017,
  title = {Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.},
  author = {von Minckwitz G and Huang CS and Mano MS and Loibl S and Mamounas EP and Untch M and Wolmark N and Rastogi P and Schneeweiss A and Redondo A and Fischer HH and Jacot W and Conlin AK and Arce-Salinas C and Wapnir IL and Jackisch C and DiGiovanna MP and Fasching PA and Crown JP and Wülfing P and Shao Z and Rota Caremoli E and Wu H and Lam LH and Tesarowski D and Smitt M and Douthwaite H and Singel SM and Geyer CE Jr and KATHERINE Investigators},
  year = {2019},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa1814017},
  url = {https://doi.org/10.1056/nejmoa1814017}
}

RIS

TY  - JOUR
TI  - Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
AU  - von Minckwitz G
AU  - Huang CS
AU  - Mano MS
AU  - Loibl S
AU  - Mamounas EP
AU  - Untch M
AU  - Wolmark N
AU  - Rastogi P
AU  - Schneeweiss A
AU  - Redondo A
AU  - Fischer HH
AU  - Jacot W
AU  - Conlin AK
AU  - Arce-Salinas C
AU  - Wapnir IL
AU  - Jackisch C
AU  - DiGiovanna MP
AU  - Fasching PA
AU  - Crown JP
AU  - Wülfing P
AU  - Shao Z
AU  - Rota Caremoli E
AU  - Wu H
AU  - Lam LH
AU  - Tesarowski D
AU  - Smitt M
AU  - Douthwaite H
AU  - Singel SM
AU  - Geyer CE Jr
AU  - KATHERINE Investigators
PY  - 2019
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa1814017
UR  - https://doi.org/10.1056/nejmoa1814017
ER  -

APA

G, V. M., CS, H., MS, M., S, L., EP, M., M, U., N, W., P, R., A, S., A, R., HH, F., W, J., AK, C., C, A., IL, W., C, J., MP, D., PA, F., JP, C., P, W., Z, S., E, R. C., H, W., LH, L., D, T., M, S., H, D., SM, S., Jr, G. C., & Investigators, K. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.. The New England journal of medicine. https://doi.org/10.1056/nejmoa1814017

Source records

pubmed · retrieved 2026-09-25T09:23:48.602Z
europe-pmc · retrieved 2026-09-25T09:23:48.593Z
hal · retrieved 2026-09-25T09:23:48.650Z